Latest Articles

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry

Diabetes management during Ramadan

iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients

EAS guidance regarding combining Lipid-modifying therapy

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM

Relationship Between LDL-C LLTs and Risk of Stroke